Micropore Technologies

Executive Summary

Micropore Technologies, based in Newcastle upon Tyne, UK, specializes in scalable membrane emulsification and encapsulation technology for advanced particle engineering. Its platform enables precise and reproducible manufacturing of micro- and nanoparticles, including lipid nanoparticles (LNPs), liposomes, and PLGA microspheres. By addressing the critical challenge of seamless scale-up from lab to commercial production, Micropore's technology accelerates R&D in drug delivery while ensuring consistent product quality. Founded in 2008 and privately held, the company targets the growing demand for complex injectable formulations, particularly in mRNA therapeutics and generic injectables. The company's membrane emulsification platform offers distinct advantages over traditional methods, including lower shear, higher encapsulation efficiency, and linear scalability. As the pharmaceutical industry increasingly adopts LNPs for vaccines and gene therapies, Micropore stands to benefit from outsourcing partnerships and technology licensing. Recent industry trends toward continuous manufacturing and quality-by-design further support its value proposition. While revenue and funding details remain undisclosed, Micropore's strategic position in the contract development and manufacturing organization (CDMO) ecosystem and its focus on high-growth drug delivery applications underpin its growth potential.

Upcoming Catalysts (preview)

• Q4 2026Pharmaceutical partnership for LNP manufacturing65% success
• Q1 2027Launch of next-gen high-throughput emulsification system55% success
• Q3 2026ISO 13485 certification for medical device quality management80% success